Bionano Genomics, Inc. (NASDAQ:BNGO)
BioNano Genomics, Inc. operates as a life sciences instrumentation company in the genome analysis space. The Company offers proprietary nanochannel chips, automated imaging instrument, integrated primary and secondary software, and application specific reagents. BioNano Genomics, Inc. is based in San Diego, United States.
Bionano Genomics, Inc. (NASDAQ:BNGO)’s Financial Overview
Bionano Genomics, Inc. (NASDAQ) surged 3.77% yesterday to close its trading session at $4.4. The company has 1 year Price Target of $11.5. Bionano Genomics, Inc. has 52-Week high of $10 and 52-Week Low of $3.5. The stock touched its 52-Week High on 10.00 and 52-Week Low on 3.50. The stock traded with the volume of 16625 shares yesterday. The firm shows the market capitalization of $44 Million.
Bionano Genomics, Inc. (NASDAQ) reported its last quarterly earnings on 9/29/2018 where the firm reported its Actual EPS of $-0.63/share against the analyst consensus estimate of $-0.49/share. The difference between the actual and expected EPS is $-0.14 a share with a surprise factor of -28.6%.
The firm is trading with SMA20 of 1.01 Percent, SMA50 of -20.41 Percent and SMA200 of -28.09 percent. Bionano Genomics, Inc. has P/S value of 4.07 while its P/B value stands at 4.31. Similarly, the company has Return on Assets of 0 percent, Return on Equity of 0 percent and Return on Investment of 53.4 Percent. The company shows Gross Margin and Operating Margin of 33.4 percent and 0 percent respectively.
The Stock currently has Analyst’ mean Recommendation of 0 where the scale is from 1 to 5, 1 means Strong Buy and 5 means Sell.
The 2 analysts offering 12-month price forecasts for BioNano Genomics Inc have a median target of 11.50, with a high estimate of 12.00 and a low estimate of 11.00. The median estimate represents a +161.36% increase from the last price of 4.40.
Bionano Genomics, Inc. is estimated to report earnings on 02/06/2019. The upcoming earnings date is derived from an algorithm based on a company’s historical reporting dates.Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date.
Core Laboratories N.V. (NYSE:CLB)
Core Laboratories N.V. is a leading provider of proprietary and patented Reservoir Description and Production Enhancement services. Core Laboratories’ reservoir optimization technologies are used to increase total recovery from existing fields. Core Laboratories’ services enable clients to optimize reservoir performance and maximize hydrocarbon recovery from their producing fields. Core Laboratories has taken extensive measures to ensure the services and data provided by all of worldwide companies are of the highest quality and integrity. Core Laboratories’ commitment to applying and developing new technologies to optimize reservoir performance is unsurpassed in the oilfield service industry. This commitment to technology and to your bottom line makes Core Laboratories, The Reservoir Optimization Company.
Core Laboratories N.V. (NYSE:CLB)’s Financial Outlook
The 17 analysts offering 12-month price forecasts for Core Laboratories NV have a median target of 75.00, with a high estimate of 120.00 and a low estimate of 61.00. The median estimate represents a +17.87% increase from the last price of 63.63.
Our vendor, Zacks Investment Research, hasn’t provided us with the upcoming earnings report date.
According to Zacks Investment Research, Core Laboratories N.V. has a Consensus Recommendation of 2.33. (The Scale is from 1-5 where 1 means Strong Buy and 5 means Strong Sell).
The Stock declined -6.26% and closed its last trading session at $63.63. The company has the market capitalization of $2.81 Billion. The stock has 52-week high of $130.34 and 52-Week low of $56.72. The firm touched its 52-Week high on 130.34 and 52-Week low on 56.72. The company has volume of 772489 shares. The company has a total of 44.22 Million shares outstanding.
Core Laboratories N.V. (NYSE) in the last quarter reported its actual EPS of $0.64/share where the analyst estimated EPS was $0.63/share. The difference between the actual and Estimated EPS is $0.01. This shows a surprise factor of 1.6 percent.
The company has YTD performance of 6.65 percent. Beta for Core Laboratories N.V. stands at 1.88 while its ATR (average true range) is 2.61. The company has Weekly Volatility of 3.13%% and Monthly Volatility of 3.47%%.
Core Laboratories N.V. has distance from 20-day Simple Moving Average (SMA20) of -6.51%, Distance from 50-Day Simple Moving Average of -7.43 percent and Distance from 200-Day Simple Moving Average of -37.34%.
The Company currently has ROA (Return on Assets) of 15.1 percent, Return on Equity (ROE) of 61.2 Percent and Return on Investment (ROI) of 25.7% with Gross margin of 29.5 percent and Operating & Profit margin of 19% and 13.2% respectively.